Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

2(66.7%)

Phase 1

1(33.3%)

3Total

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03815331Phase 4Completed

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

Role: lead

NCT03091348Phase 4Completed

Subcutaneous vs. Intramuscular Testosterone

Role: lead

NCT01963390Completed

Metabolomics During Testosterone Therapy

Role: lead

NCT01578473Phase 1Completed

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

Role: lead

NCT03091296Completed

Diurnal Testosterone Concentration

Role: lead

All 5 trials loaded